Therapeutic Response

PD-L1 >= 50%, Wild type ALK, and Wild type EGFR status confers therapeutic sensitivity to Pembrolizumab in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Keytruda (pembrolizumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors express PD-L1 with a >= 50% tumor proportion score (TPS) with no EGFR or ALK positive tumor mutations.